The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials

Table 4 The influence on lymphocyte subsets

Lymphocyte subsets	Included studies	Cases	Chi	I² %	SMD	95 % CI	P
CD3	9 [25, 28, 31, 33, 35, 36, 38, 42, 43]	521	56.12	86 %	0.84	0.35,1.33	0.0008
CD4	14 [25–28, 30, 31, 33–38, 42, 43]	779	51.01	75 %	0.80	0.50,1.10	<0.0001
CD8	12 [25, 26, 28, 30, 31, 33–37, 42, 43]	695	62.64	82 %	−0.27	−0.64,0.10	0.16
CD4/ CD8	13 [25, 27, 28, 30, 31, 33, 35–39, 42, 43]	1038	102.37	88 %	0.62	0.22,1.02	<0.0001

ISSN: 1471-2334